^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NM21-1480

    i
    Other names: ND-021, CS-2006, NM211480, ND 021, CS 2006, NM21 1480, NM21-1480, ND021, PD-L1/4-1BB/HSA trispecific scDb-scFv , CS2006
    Associations

    News

    Trials
    Company:
    CStone Pharma, Numab
    Drug class:
    PD-L1 inhibitor, CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    10ms
    A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=52, Terminated, Numab Therapeutics AG | N=406 --> 52 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Feb 2024; A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
    Enrollment change • Trial termination • Trial primary completion date • Trispecific • Metastases
    |
    NM21-1480
    12ms
    A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=406, Active, not recruiting, Numab Therapeutics AG
    Trial completion date • Trispecific • Metastases
    |
    NM21-1480
    1year
    A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=406, Active, not recruiting, Numab Therapeutics AG | Recruiting --> Active, not recruiting
    Enrollment closed • Trispecific • Metastases
    |
    NM21-1480
    over1year
    An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin. (PubMed, Oncoimmunology)
    In xenograft models, NM28-2746 exhibited significant tumor suppressing activity, which was significantly enhanced by combination therapy with NM21-1480. NM28-2746, alone or in combination with NM21-1480, may overcome shortcomings of previous MSLN-targeted immuno-oncology drugs, exhibiting enhanced discrimination of high MSLN-expressing cell activity in the presence of sMSLN.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    NM21-1480 • NM28-2746